Belantamab mafodotin for relapsed/refractory multiple myeloma: a real-world observational study update

被引：0

作者：

Hultcrantz, Malin ^{[1
]}

Kleinman, David ^{[2
]}

Vij, Ravi ^{[3
]}

Escalante, Fernando ^{[4
]}

Delforge, Michel ^{[5
]}

Kotowsky, Nirali ^{[6
]}

Bitetti, Jacopo ^{[7
]}

Boytsov, Natalie ^{[6
]}

Camadoo-O'Byrne, Leena ^{[8
]}

Happ, Lindsey Powers ^{[9
]}

Rohman, Mujib ^{[10
]}

Germain, Guillaume ^{[11
]}

Duh, Mei Sheng ^{[12
]}

Laliberte, Francois ^{[11
]}

Mahendran, Malena ^{[11
]}

Urosevic, Ana ^{[11
]}

Lee, Hans ^{[13
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY USA

[2] Univ Rochester, Flaum Eye Inst, Med Ctr, Rochester, NY USA

[3] Washington Univ, Div Oncol, Sch Med, St Louis, MO USA

[4] Univ Hosp Leon, Dept Hematol, Leon, Spain

[5] Univ Leuven, Leuven, Belgium

[6] GSK, Upper Providence, PA USA

[7] GSK, Zug, Switzerland

[8] GSK, Stevenage, Herts, England

[9] GSK, Collegeville, PA USA

[10] GSK, Windsor, England

[11] Ltee, Grp Anal, Montreal, PQ, Canada

[12] Anal Grp Inc, Boston, MA USA

[13] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-272

引用

页码：S185 / S186

页数：2

共 50 条

[31] Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma
Yifei Zhang
Amandeep Godara
Stacey Pan
Denis Toskic
Hashim Mann
Douglas Sborov
Raymond Comenzo
Ankit Kansagra
[J]. Annals of Hematology, 2022, 101 : 2119 - 2121
[32] OUTCOMES OF IDECABTAGENE VICLEUCEL IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PREVIOUSLY TREATED WITH BELANTAMAB MAFODOTIN
Melody, Megan
Przybylski, Daniel
Robinson, Adam
Lin, Adam
Gordon, Leo
Adekola, Kehinde
Singhal, Seema
Mehta, Jayesh
Moreira, Jonathan
[J]. BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 210 - 211
[33] Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in RealLife Setting: The ALFA Study
Roussel, Murielle
Texier, Nathalie
Germain, Raphael
Sapra, Sandhya
Paka, Prani
Kerbouche, Naima
Colin, Xavier
Leleu, Xavier
[J]. BLOOD, 2022, 140 : 4261 - 4263
[34] Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma
Wahab, Ahsan
Rafae, Abdul
Mushtaq, Kamran
Masood, Adeel
Ehsan, Hamid
Khakwani, Maria
Khan, Aqsa
[J]. FRONTIERS IN ONCOLOGY, 2021, 11
[35] Phase I/II Study of Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone (BelCyd) in Relapsed/Refractory Multiple Myeloma
Badros, Ashraf Z.
Nash, Thea
Lawrance, Christopher
Tittle, Brandon
Philip, Sunita
Sunshine, Sarah
Munir, Wuqaas
Fan, Xiaoxuan
Ide, Christina
Atanackovic, Djordje
[J]. BLOOD, 2023, 142
[36] Belantamab mafodotin in multiple myeloma
Martino, Enrica Antonia
Bruzzese, Antonella
Iaccino, Enrico
Labanca, Caterina
Mendicino, Francesco
Mimmi, Selena
Lucia, Eugenio
Olivito, Virginia
Neri, Antonino
Morabito, Fortunato
Vigna, Ernesto
Gentile, Massimo
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (11) : 1043 - 1047
[37] EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma
Tzogani, Kyriaki
Penttil, Karri
Lahteenvuo, Johanna
Lapvetelainen, Tuomo
Lopez Anglada, Lucia
Prieto, Carolina
Garcia-Ochoa, Blanca
Enzmann, Harald
Gisselbrecht, Christian
Delgado, Julio
Pignatti, Francesco
[J]. ONCOLOGIST, 2021, 26 (01): : 70 - 76
[38] Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
Nooka, Ajay K.
Weisel, Katja
van de Donk, Niels W. C. J.
Routledge, David
Otero, Paula Rodriguez
Song, Kevin
Quach, Hang
Callander, Natalie
Minnema, Monique C.
Trudel, Suzanne
Jackson, Nicola A.
Ahlers, Christoph M.
Im, Ellie
Cheng, Shinta
Smith, L.
Hareth, Nahi
Ferron-Brady, Geraldine
Brouch, Maria
de Oca, Rocio Montes
Paul, Sofia
Holkova, Beata
Gupta, Ira
Kremer, Brandon E.
Richardson, Paul
[J]. FUTURE ONCOLOGY, 2021, 17 (16) : 1987 - 2003
[39] Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study
Talbot, Alexis
Bobin, Arthur
Tabone, Lea
Lambert, Jerome
Boccaccio, Catherine
Deal, Cecile
Petillon, Marie-Odile
Allangba, Olivier
Agape, Philippe
Arnautou, Pierre
Belkhir, Rakiba
Cailleres, Sylvie
Chaoui, Driss
Chretien, Marie-Lorraine
Decaux, Olivier
Schulmann, Samantha
Frenzel, Laurent
Gastaud, Lauris
Huart, Antoine
Hulin, Cyrille
Karlin, Lionel
Laribi, Kamel
Le Calloch, Ronan
Lenain, Pascal
Macro, Margaret
Manier, Salomon
Montes, Lydia
Moreau, Stephane
Moreau, Philippe
Morel, Veronique
Norwood, James
Piocelle, Frederique Orsini
Perrot, Aurore
Pica, Gian Matteo
Rey, Philippe
Schmitt, Anna
Stoppa, Anne-Marie
Tiab, Mourad
Touzeau, Cyrille
Vidal, Valerie
Vignon, Marguerite
Vincent, Laure
Van De Wyngaert, Zoe
Zarnitsky, Charles
Kerbouche, Naima
Paka, Prani
Leleu, Xavier
Arnulf, Bertrand
Avet-Loiseau, Herve
[J]. HAEMATOLOGICA, 2023, 108 (10) : 2774 - 2782
[40] Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy
Fazio, Francesca
Petrucci, Maria Teresa
Corvatta, Laura
Piciocchi, Alfonso
Pepa, Roberta Della
Tacchetti, Paola
Musso, Maurizio
Zambello, Renato
Belotti, Angelo
Bringhen, Sara
Antonioli, Elisabetta
Conticello, Concetta
Renzo, Nicola Di
De Stefano, Valerio
Musto, Pellegrino
Gamberi, Barbara
Derudas, Daniele
Boccadoro, Mario
Offidani, Massimo
More, Sonia
[J]. EJHAEM, 2024, 5 (03): : 485 - 493

← 1 2 3 4 5 →